Anthony Doyle - 15 Dec 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief Financial Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 15 Dec 2022
Transactions value $: -$62,130
Form type: 4
Filing time: 19 Dec 2022, 15:55:39 UTC
Previous filing: 13 Jan 2022
Next filing: 21 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Sale	-$62.1K	-5.7K	-3.36%	$10.90	164K	15 Dec 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 18,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Content

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2022 to cover tax withholding obligations in connection with the vesting of 18,750 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.